PETALING JAYA: Pharmaniaga Bhd’s net profit slumped 72.6% to RM3.58 million for the third quarter ended September 30, 2017 against RM13.06 million in the previous corresponding period, dragged down by lower off-take for in-house products, higher cost of sales and taxation.
Its revenue, however, increased 11.5% from RM515.22 million to RM574.5 million.
The group has proposed to declare an interim dividend of 5 sen per share for the quarter under review, payable on December 15.
Pharmaniaga said in a filing with the stock exchange that its top line growth was bolstered by solid contributions from its businesses, particularly its overseas operations.
Moving forward, Pharmaniaga said the group is on track to deliver new product offerings for both local and overseas markets for the coming years ahead, which should further strengthen earnings potential.
Over the long-term, it is of the view that the group’s prospects remain positive and is well prepared to tap into the opportunities following the initiatives announced by the government under Budget 2018.
“From the total allocation of RM27 billion to provide quality healthcare services, RM2.5 billion has been allocated for medical suppliers and RM1.6 billion for consumable and medical support items. Along with this, funds have been allocated for the treatment of increasing cases of rare diseases and a programme to raise awareness on non-communicable diseases.”
Pharmaniaga’s nine-month net profit fell 31% from RM46.44 million to RM32.02 million, with revenue rising 6.5% from RM1.61 billion to RM1.71 billion.
At 12.30pm, its shares were unchanged at RM3.86 on some 178,000 shares done.
Read the original story on: TheSunDaily.My